Abstract: Eleven percent of all men will develop prostate cancer (PC). In the US, 3 million men are living with the disease, 192,000 new cases are expected, and 33,000 men will die from the illness this year. PC is the second leading cause of cancer (CA) deaths in men worldwide, the diagnosis of PC relies on a combination of tests and procedures, including the digital rectal exam (DRE), magnetic resonance imaging (MRI), ultrasound, and multiple tissue biopsies, each with escalating costs and risks. In 2018, the cost of PC care in the US was $15.3 billion dollars, of which $5.7 billion was spent on diagnosis and $8.3 billion on management. There is a critical need for an early, accurate, reliable and cancer specific diagnostic for PC. The technology as described herein relates to compositions and methods for diagnosing and staging of cancer in a subject.